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JOURNAL OF HEPATOLOGYIL28B polymorphism and hepatitis C: A genetic marker
of peginterferon-a sensitivity devoid from classical
interferon-a side effects?To the Editor:
Single nucleotide polymorphism (SNP) in the region of the inter-
leukin-28B (IL28B) gene has recently been associated with spon-
taneous and treatment-induced clearance of hepatitis C virus
infection [1–3]. The SNPs are located near the IL28B gene of chro-
mosome 19, implicating a role for its gene product, interferon-k3,
in the immune response to hepatitis C virus. The mechanisms by
which IL28B polymorphism effects the sensitivity to exogenous
peginterferon-a therapy is unclear at present.
We have read with interest the recent genome-wide associa-
tion study by Thompson et al. on peginterferon-a-induced cyto-
penia in chronic hepatitis C patients [4]. The authors state that
none of the IL28B polymorphisms known to be associated with
treatment induced viral clearance, correlated with the typical
peginterferon-a side effects thrombocytopenia and neutropenia
after 4 weeks of treatment. The authors suggest a possible liver
speciﬁcity of interferon-k by which the favorable IL28B polymor-
phism might result in increased viral clearance from the liver
with a reduced propensity for interferon-a-induced bone marrow
suppression.
We have three concerns regarding the study that might inﬂu-
ence interpretation of the observations made by the authors.
In the Individualized Dosing Efﬁcacy versus Flat Dosing to
Asses Optimal Pegylated Interferon Therapy (IDEAL) study,
3070 patients were treated, of whom 1654 completed the treat-
ment [5]. The patient group of the current GWAS study consisted
of 1284 out of 1604 patients who consented to genetic testing
and fulﬁlled the 80/80/80 adherence criteria. The majority of
patients studied in this analysis, therefore, probably derive from
the 1654 who completed treatment. Limiting the analysis to
adherent patients when studying dose-related side effects such
as peginterferon-induced cytopenia may appear justiﬁed at ﬁrst
glance. This approach, however, excludes the data from patients
who had dose reductions or were not able to complete treatment
for other peginterferon side effects, but who may have had con-
comitant peginterferon-induced cytopenias.
In the IDEAL study, patients were treated with either peginter-
feron-a-2b 1 lg/kg, 1.5 lg/kg or peginterferon-a-2a 180 lg/kg
weekly on a 1/1/1 randomized basis in combination with ribavi-
rin oral therapy [5]. The proportions of patients with neutropenia
who met the criterion for per protocol peginterferon-dose
reduction in this study were 12.5%, 19.4% and 21.1% of theJournal of Hepatology 20patients treated with the low-dose peginterferon-a-2b (1 lg/kg)
versus the standard-dose peginterferon-a-2b (1.5 lg/kg) and
peginterferon-a-2a (180 lg/kg), respectively. The inclusion of
the low-dose peginterferon-a-2b arm in the current analy-
sis therefore obscures the severity of the observed cytopenias
in the two arms that were treated with the standard dose of
either peginterferon-a that is relevant for current clinical
practice.
In two recent publications by our group on peginterferon-
a-induced cytopenia, thrombocytopenia and neutropenia pro-
gressed to a nadir after 12 and 14 weeks of peginterferon-a
treatment, respectively [6,7]. The analysis performed by the
authors after only 4 weeks of treatment might therefore
underscore the severity of true peginterferon-a-induced cytope-
nia, obscuring a possible link with baseline IL28B polymorphism
as a marker of interferon sensitivity.
To rule out an inclusion bias, it is necessary to demonstrate
that the cytopenias observed in the reported 1284 patients do
not differ from those observed in the 1466 patients who did
not consent to genetic testing or in the 320 patients who did con-
sent but are not included in the analysis. We are also interested
to learn from the authors whether the absence of correlation with
IL28B polymorphism and peginterferon-induced cytopenia would
hold if the analysis were to be performed in both adherent and
non-adherent patients under treatment at week 12 and 18 from
the two standard peginterferon-a-2b 1.5 lg/kg and peginterfer-
on-a-2a 180 lg dosing groups, omitting the data from the low-
dose peginterferon-a-2b (1.0 lg/kg) group. An analysis of the
IL28B genotype distribution in the so-called ‘‘non-adherent’’ pop-
ulation that consented to genetic testing in comparison to the
reported ‘‘adherent’’ group would further help to clarify whether
a favorable IL28B polymorphism does in fact enhance viral
clearance without the occurrence of classical interferon-a side
effects.
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We appreciate the interest of Orlent et al. in our recent study
[1] and would like to comment on the issues raised in their
letter.
(i) The primary endpoint we selected for all genome-wide
analyses of peginterferon (pegIFN)-induced cytopenia
was quantitative reduction in cell counts, as a continuous
variable, at week 4. We chose the continuous variable as
the primary endpoint for two reasons. Firstly, this method
maximizes the statistical power of the dataset. Secondly, it
avoids the pitfalls of deﬁning pre-speciﬁed thresholds for
cytopenia, where timing and the chosen level of the
threshold are arbitrary. We chose the week 4 timepoint
to minimize confounding by dose adjustment/adherence.
It is true that week 4 preceded the nadir for pegIFN-related
thrombocytopenia and neutropenia in this study, which
occurred between week 8 and 12. However, the rate of
decline was most profound in the ﬁrst 4 weeks, with sig-
niﬁcant reductions in both platelet counts and neutrophil
counts by week 4 [1]. We have subsequently tested for
association between the IL28B polymorphism rs12979860
and quantitative reduction of platelet/neutrophil counts
at week 12. No signiﬁcant association was observed.
(ii) Orlent et al. suggested that inclusion of patients treated
with low-dose pegIFN-a-2b in our analysis may have
confounded the results. We included these patients to
maximize the sample size. We did adjust for pegIFN dose
however, as stated in the methodology [1], by coding a
binary variable for full vs. low dose pegIFN. This variable
was included in all statistical models. PegIFN dose
was signiﬁcantly associated with both thrombocytopenia
and neutropenia as expected. IL28B polymorphism was
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not signiﬁcantly associated with pegIFN-cytopenia when
analysis was limited to patients receiving full-dose
pegIFN.
(iii) Orlent et al. also raised the possibility of inclusion bias. It
is true that we limited the analysis of week 4 cytopenia to
patients who were at least 80% adherent to study treat-
ment to this timepoint. This decision was taken to reﬁne
the clinical phenotype. However, it should be noted that
only 26 patients were excluded from the analyses of
platelet/neutrophil counts on the basis of adherence at
the week 4 timepoint [1]. Inclusion of these 26 patients
into the analysis does not change the results of the anal-
yses. The majority of the patients who consented to
genetic testing, but were not included in this analysis,
were excluded on the basis of genotyping quality control
or missing data points (only patients with complete data-
sets for all relevant variables could be included in the
analyses). There was no signiﬁcant difference in the
median reductions of platelet counts or neutrophil counts
comparing patients who were included in the ﬁnal analy-
sis vs. patients who consented to genetic testing but were
not included in the ﬁnal analyses (patients of European
American, African American and Hispanic ethnicity con-
sidered separately). We therefore feel that inclusion bias
within this study was unlikely. We have recently ana-
lyzed the overall IDEAL cohort for patient factors that
might inﬂuence consent to the performance of genetic
testing and the data will be presented at AASLD 2011
[2]. There were no differences in treatment outcomes or
overall adverse events (including cytopenia) between
patients who did, or did not consent, to participation in
the pharmacogenomics substudy.
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